Chemours (NYSE: CC) reported Q2 EPS of $1.89, $0.48 better than the analyst estimate of $1.41. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.84 billion.

Adjusted EBITDA for FY 2022 is now expected to be at the high end of the previously updated guidance range of $1.475 billion to $1.575 billion. We now expect Free Cash Flow to exceed $600 million vs. our previous guidance of greater than $550 million.

For earnings history and earnings-related data on Chemours (CC) click here.